Impact of re‐transurethral resection of bladder staging on risk stratification of high‐grade T1 non‐muscle‐invasive bladder cancer across European Association of Urology 2021 risk groups
BJU International · 2026-05 · 137 (5) · 866-876
DOI: 10.1111/bju.70207 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift BJU International, online erschienen am 03.03.2026. Verfasst von Ana Fernández-Mardomingo und 44 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. Hauptthemen laut MEDLINE: Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
Objective
To evaluate the prognostic impact of T‐stage at re‐transurethral resection of bladder (TURB) and its utility for refining risk stratification across European Association of Urology 2021 (EAU21) risk groups in patients with T1 high‐grade (HG) non‐muscle‐invasive bladder cancer (NMIBC) treated with adequate Bacillus Calmette–Guérin (BCG). Patients and Methods Retrospective multicentre study including patients with primary or secondary T1HG NMIBC treated with TURB, re‐TURB, and adequate BCG between 2007 and 2020 across 28 European academic centres. Patients were stratified according to re‐TURB pathological stage (T0, Ta, Tis, T1) and EAU21 risk groups. Kaplan–Meier, Cox regression, and competing‐risk methods were used to evaluate recurrence‐free survival (RFS), HG‐RFS, progression‐free survival (PFS), and cancer‐specific mortality (CSM). A mixture cure model estimated statistical cure fractions for the overall cohort.
Results
Among 1403 patients, residual disease at re‐TURB was identified in 38.8%, including 17.7% with persistent T1. Residual T1 was consistently associated with worse outcomes. Compared with T0/Ta, persistent T1 at re‐TURB showed substantially lower 5‐year HG‐RFS and PFS, with high‐grade recurrence in over half of patients and 5‐year progression up to 48% in high‐ and very high‐risk groups. The 5‐year CSM rose from 6–7% (T0/Ta) to 23% (T1). On multivariable analysis, residual T1 was independently associated with worse HG‐RFS (hazard ratio 2.40), PFS (hazard ratio 3.10), and CSM (hazard ratio 3.00). Cure modelling showed lower cure fractions for residual T1 compared with T0/Ta.
Conclusion
Residual T1 at re‐TURB is strongly associated with adverse long‐term oncological outcomes in BCG‐treated T1HG NMIBC and markedly reduces the likelihood of statistical cure. High‐ and very high‐risk patients with persistent T1 represent a biologically adverse subgroup in whom standard BCG may be insufficient.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain.
- Department of Minimally Invasive Robotic Urology, Center of Excellence in Urology, Wrocław Medical University, Wrocław, Poland.
- Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria.
- Department of Urology, Clínica Universidad de Navarra, Madrid, Spain.
- Servicio de Urología, Hospital Universitario Rey Juan Carlos, Universidad Rey Juan Carlos Móstoles, Madrid, Spain.
- Division of Experimental Oncology, Department of Urology, Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy.
ORCID-Profile: Ana Fernández-Mardomingo, Jose Daniel Subiela, Alberto Artiles Medina, Renate Pichler, Daniel A González-Padilla, Marco Moschini, Mario de Angelis, Roberto Contieri, Andrea Gallioli, David D'Andrea, Tarek Ajami, Francesco Del Giudice, Aleksander Ślusarczyk, Simone Albisinni, Francesco Soria, Laura S Mertens, Karl Tully, Andrea Mari, Félix Guerrero-Ramos, Luca Afferi, Ana Saiz
Zitieren
APA
Fernández-Mardomingo, A., Subiela, J. D., Artiles Medina, A., Krajewski, W., Pichler, R., van Creij, N. C. H., de la Estella Lucena, M. P., de la Parra, I., Mínguez Ojeda, C., Coloma, A., Crespo Martínez, L., Del Olmo Durán, P., González-Padilla, D. A., Villacampa, F., Aumatell, J., Scilipoti, P., Longoni, M., Moschini, M., de Angelis, M., …, & Young Academic Urologist: Urothelial Carcinoma Working Group (2026). Impact of re‐transurethral resection of bladder staging on risk stratification of high‐grade T1 non‐muscle‐invasive bladder cancer across European Association of Urology 2021 risk groups. BJU International, 137(5), 866-876. https://doi.org/10.1111/bju.70207
Vancouver
Fernández-Mardomingo A, Subiela JD, Artiles Medina A, Krajewski W, Pichler R, van Creij NCH, et al. Impact of re‐transurethral resection of bladder staging on risk stratification of high‐grade T1 non‐muscle‐invasive bladder cancer across European Association of Urology 2021 risk groups. BJU International. 2026;137(5):866-876. doi:10.1111/bju.70207
BibTeX
@article{FernndezMardomingo2026,
author = {Fernández-Mardomingo, Ana and Subiela, Jose Daniel and Artiles Medina, Alberto and Krajewski, Wojciech and Pichler, Renate and van Creij, Nils C H and de la Estella Lucena, María de la Palma and de la Parra, Irene and Mínguez Ojeda, Cesar and Coloma, Almudena and Crespo Martínez, Luis and Del Olmo Durán, Pedro and González-Padilla, Daniel A and Villacampa, Felipe and Aumatell, Júlia and Scilipoti, Pietro and Longoni, Mattia and Moschini, Marco and de Angelis, Mario and Caño-Velasco, Jorge and Contieri, Roberto and Gallioli, Andrea and D'Andrea, David and Acosta, Eduardo Albers and Ajami, Tarek and Grobet-Jeandin, Elisabeth and Del Giudice, Francesco and Santarelli, Valerio and Ślusarczyk, Aleksander and Albisinni, Simone and Soria, Francesco and Mertens, Laura S and Tully, Karl and Mari, Andrea and Guerrero-Ramos, Félix and Alvarez-Maestro, Mario and Anagua Melendres, Franklin and Buisan, Oscar and Afferi, Luca and Gajate, Pablo and Guerrero, Patricia and Saiz, Ana and Pradere, Benjamin and Burgos Revilla, Francisco Javier and Young Academic Urologist: Urothelial Carcinoma Working Group, Young Academic Urologist: Urothelial Carcinoma Working Group},
title = {Impact of re‐transurethral resection of bladder staging on risk stratification of high‐grade T1 non‐muscle‐invasive bladder cancer across European Association of Urology 2021 risk groups},
journal = {BJU International},
year = {2026},
volume = {137},
number = {5},
pages = {866--876},
doi = {10.1111/bju.70207}
}
EUVIMED